Acne Scars - Mixed Atrophic and Hypertrophic Clinical Trial
Official title:
Safety and Efficacy of Sofwave Treatment for Acne Scars Appearance Improvement
Verified date | April 2023 |
Source | Sofwave Medical LTD |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.
Status | Completed |
Enrollment | 60 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 22 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Healthy male or female subjects > 22 years of age and < 80 years of age. 2. For female subjects, not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence. 3. Seeking treatment for facial acne scars. 4. Have visible mild to moderate facial acne scars. 5. Agree not to undergo any other facial acne scars treatments for a period of 3 months following Sofwave treatments. 6. Willing to have photographs of the treated areas. Agree for de-identified study images to be used in evaluations, publications and presentations. 7. Able and willing to comply with all visits, treatments and evaluations schedules and requirements. 8. Able to understand and provide written Informed Consent Exclusion Criteria: 1. Pregnant or planning to become pregnant during the duration of the study, having given birth less than 3 months ago, and/or breast feeding 2. Current smoker or has history of heavy smoking (25 cigarettes per day or more) in past 10 years. 3. History of severe migraine tendency. 4. History of Epileptic seizures. 5. History of chronic drug or alcohol abuse. 6. Taking Isotretinoin or other oral retinoid within the past 6 months; taking anti-platelet or anti-coagulant within the past 2 weeks. 7. Medical disorder that may hinder the wound healing or immune response (such as blood disorder, inflammatory disease, etc.) 8. Presence of a metal stent or implant in the facial area. 9. Known allergy to tetracaine, Xylocaine or epinephrine. 10. Active malignancy or history of malignancy in the past 5 years. 11. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the investigator may interfere with the anesthesia, treatment, or healing process). 12. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications. 13. Presence of any active systemic or local infections. 14. Severe or cystic facial acne, acutance uses during past 6 months. 15. History of cosmetic treatments in the facial area to be treated, including facial skin-tightening procedure within the 6 months; injectable (Botox or fillers of any type) within the 6 months; ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep facial peels within the past 12 months; facelift or blepharoplasty within the past 12 months. 16. Inability to understand the protocol or to give informed consent 17. On-going use of psychiatric medication 18. Unable or unwilling to comply with the study requirements and procedures 19. Currently enrolled in a clinical study of any other unapproved investigational drug or device 20. As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study. |
Country | Name | City | State |
---|---|---|---|
United States | SLSS, a Division of Schweiger Dermatology Group Research Office | Hackensack | New Jersey |
United States | Laser & Skin Surgery Center of New York® | New York | New York |
United States | New York Laser & Skin Care | New York | New York |
United States | UnionDerm | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Sofwave Medical LTD |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of change of acne scars appearance, as assessed by independent masked evaluators at 3 months post last treatment session. | following Sofwave treatments based on 6 points simplified Acne Severity Scale (ASS), as evaluated by independent masked reviewers. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04559022 -
Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring
|
N/A | |
Active, not recruiting |
NCT06192550 -
Functional Usability and Feasibility Testing of the Profound Matrix™ System
|
N/A | |
Recruiting |
NCT05362929 -
Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color
|
N/A | |
Recruiting |
NCT05597267 -
The MIRIA Acne Scar Study
|
N/A | |
Completed |
NCT05691049 -
Evaluation of Efficacy and Safety of HCC_45 for the Correction of Acne Scars of the Face
|
N/A | |
Active, not recruiting |
NCT02592993 -
Performance of PicoWayTM Picosecond Fractional Laser for Acne Scars
|
N/A | |
Completed |
NCT04827680 -
Clinical Evaluation of the Safety and Performance of FRF for the Treatment and Reduction of Acne Scarring
|
N/A | |
Completed |
NCT03988049 -
Comparison of 1,550 and 755 Laser in a Split-face Trial
|
N/A | |
Not yet recruiting |
NCT05597813 -
Topical Timolol 0.5% in Atrophic Acne Scar
|
N/A | |
Completed |
NCT03284333 -
enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars
|
N/A | |
Completed |
NCT03514771 -
Early Non-Ablative Fractional Laser Resurfacing for Acne Scars After Treatment With Oral Isotretinoin
|
N/A | |
Not yet recruiting |
NCT06102343 -
Safety and Efficacy Investigation on the Effects of ClearSkin Non-ablative ER:Glass 1540nm Laser Module in the Treatment of Acne Scars.
|
N/A | |
Not yet recruiting |
NCT05600075 -
Microneedling With Topical Preparations in the Treatment of Atrophic Post-acne Scars
|
N/A | |
Not yet recruiting |
NCT04252352 -
Treatment of Acne Scars With Fractional CO2 Laser Versus Radio-frequency Microneedling
|
N/A | |
Completed |
NCT04606134 -
Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring
|
N/A | |
Completed |
NCT04057768 -
Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles
|
N/A |